Dicerna Pharmaceuticals, Inc. (DRNA): Price and Financial Metrics


Dicerna Pharmaceuticals, Inc. (DRNA): $20.77

-0.10 (-0.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DRNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 503

in industry

DRNA POWR Grades


  • DRNA scores best on the Value dimension, with a Value rank ahead of 85.33% of US stocks.
  • DRNA's strongest trending metric is Growth; it's been moving down over the last 52 weeks.
  • DRNA's current lowest rank is in the Momentum metric (where it is better than 9.5% of US stocks).

DRNA Stock Summary

  • Price to trailing twelve month operating cash flow for DRNA is currently 58.3, higher than 91.91% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of 187.9%, Dicerna Pharmaceuticals Inc's debt growth rate surpasses 95.02% of about US stocks.
  • As for revenue growth, note that DRNA's revenue has grown 99.54% over the past 12 months; that beats the revenue growth of 93.35% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Dicerna Pharmaceuticals Inc, a group of peers worth examining would be SLDB, RARE, SRRK, MORF, and RGNX.
  • DRNA's SEC filings can be seen here. And to visit Dicerna Pharmaceuticals Inc's official web site, go to www.dicerna.com.

DRNA Valuation Summary

  • DRNA's price/earnings ratio is -12.4; this is 133.97% lower than that of the median Healthcare stock.
  • DRNA's price/earnings ratio has moved up 24.2 over the prior 92 months.
  • Over the past 92 months, DRNA's EV/EBIT ratio has gone up 29.6.

Below are key valuation metrics over time for DRNA.

Stock Date P/S P/B P/E EV/EBIT
DRNA 2021-08-31 8.9 14.4 -12.4 -11.2
DRNA 2021-08-30 9.1 14.7 -12.6 -11.5
DRNA 2021-08-27 9.0 14.5 -12.4 -11.3
DRNA 2021-08-26 8.7 14.1 -12.1 -10.9
DRNA 2021-08-25 9.1 14.6 -12.6 -11.4
DRNA 2021-08-24 9.0 14.4 -12.4 -11.3

DRNA Growth Metrics

  • Its year over year price growth rate is now at 16.72%.
  • The year over year revenue growth rate now stands at 224.45%.
  • The 3 year net cashflow from operations growth rate now stands at 304.19%.
DRNA's revenue has moved up $178,587,000 over the prior 67 months.

The table below shows DRNA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 178.771 27.825 -129.215
2021-03-31 177.882 -172.672 -120.22
2020-12-31 164.307 175.112 -112.747
2020-09-30 130.431 207.491 -115.831
2020-06-30 89.591 232.5 -124.772
2020-03-31 54.825 248.105 -116.797

DRNA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DRNA has a Quality Grade of C, ranking ahead of 61.82% of graded US stocks.
  • DRNA's asset turnover comes in at 0.246 -- ranking 181st of 681 Pharmaceutical Products stocks.
  • CASI, ONVO, and CPHI are the stocks whose asset turnover ratios are most correlated with DRNA.

The table below shows DRNA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.246 1 -0.325
2021-03-31 0.254 1 -0.342
2020-12-31 0.227 1 -0.342
2020-09-30 0.187 1 -0.426
2020-06-30 0.147 1 -0.498
2020-03-31 0.106 1 -0.536

DRNA Price Target

For more insight on analysts targets of DRNA, see our DRNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.89 Average Broker Recommendation 1.59 (Moderate Buy)

DRNA Stock Price Chart Interactive Chart >

Price chart for DRNA

DRNA Price/Volume Stats

Current price $20.77 52-week high $40.14
Prev. close $20.87 52-week low $18.78
Day low $20.50 Volume 291,100
Day high $21.00 Avg. volume 839,594
50-day MA $20.71 Dividend yield N/A
200-day MA $27.49 Market Cap 1.61B

Dicerna Pharmaceuticals, Inc. (DRNA) Company Bio


Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. The company was founded in 2006 and is based in Cambridge, Massachusetts.


DRNA Latest News Stream


Event/Time News Detail
Loading, please wait...

DRNA Latest Social Stream


Loading social stream, please wait...

View Full DRNA Social Stream

Latest DRNA News From Around the Web

Below are the latest news stories about Dicerna Pharmaceuticals Inc that investors may wish to consider to help them evaluate DRNA as an investment opportunity.

Hedge Fund Sentiment Is Stagnant On Dicerna Pharmaceuticals Inc (DRNA)

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | October 18, 2021

Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021

LEXINGTON, Mass., October 15, 2021--Dicerna announced an abstract on clinical data from the PHYOX™2 trial of nedosiran has been accepted as a late-breaker poster presentation at ASN.

Yahoo | October 15, 2021

Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November

LEXINGTON, Mass., October 14, 2021--Dicerna announced that two abstracts related to the Company’s clinical development programs have been accepted for poster presentations at AASLD.

Yahoo | October 14, 2021

Dicerna Pharmaceuticals (NASDAQ:DRNA) Upgraded by Zacks Investment Research to Buy

Dicerna Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past. Dicerna Pharmaceuticals Upgraded by Zacks Investment Research on 10/12/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold. The post Dicerna Pharmaceuticals (NASDAQ:DRNA) Upgraded by Zacks Investment Research to Buy appeared first on .

Stock Market Daily | October 13, 2021

How Much Of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Do Institutions Own?

A look at the shareholders of Dicerna Pharmaceuticals, Inc. ( NASDAQ:DRNA ) can tell us which group is most powerful...

Yahoo | October 12, 2021

Read More 'DRNA' Stories Here

DRNA Price Returns

1-mo 0.44%
3-mo -44.63%
6-mo -27.58%
1-year 9.03%
3-year 68.45%
5-year 411.58%
YTD -5.72%
2020 0.00%
2019 106.08%
2018 18.38%
2017 213.54%
2016 -75.74%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9215 seconds.